Oil Prices Rise as Houthi Attacks Threaten Middle East Supply 
US Stock Futures Rise as Oil Prices Fall Ahead of Q3 Earnings 
IMF Maintains 2027 Global Growth Forecast at 3.4% Amid Rising Risks 
UK Finance Minister Healey Calls for Fiscal Discipline Amid Global Risks 
Most Americans Oppose Election Betting on Prediction Markets, Poll Finds 
US Dollar Near 18-Month High Ahead of Inflation Data 
Morgan Stanley Predicts $10 Trillion RWA Market by 2030 
FAA Warns US Airlines Over Saudi Arabia Flight Risks 
Asian Currencies Steady as Dollar Nears 18-Month High Ahead of US CPI 
Samsung, SK Hynix Shares Plunge as China Chip Competition Grows 
Gold Prices Rebound as Dollar Weakens Ahead of US Inflation Data 
Airbus Tests Valkyrie Combat Drone in Europe for Eurofighter Integration 
S&P 500 Rally Masks Losses for Over 40% of Stocks in 2026 
US Dollar Rises for Fourth Week as Fed Rate Hike Bets Grow 
Elon Musk Donates $366 Million to 2026 US Midterms 
Add as a preferred source on Google
Samsung Biologics and Novartis International AG signed a contract manufacturing organization deal, and this was announced on Tuesday, June 7. The deal is worth $81 million.
According to The Korea Herald, the South Korean biotech company signed an intent letter for the CMO with the Swiss multinational pharmaceutical corporation. The agreement was announced via Samsung Biologics’ regulatory filing that also revealed that the companies signed the initial contract late last week.
Based on the report, the amount of the contract is equivalent to 6.41% of Samsung Biologics’ annual sales last year, which reached KRW1.57 trillion or around $1.25 billion. Then again, it was not mentioned which of Novartis’ biopharmaceutical products Samsung Biologics is producing under the CMO agreement.
The Korean biotech firm said that it would be releasing more deals in the future after both parties signed the main contract for their CMO partnership. The collab is said to be the first time Samsung Biologics is securing a deal from the Swiss pharmaceutical company.
“The letter of intent was the first contract between the two firms,” an official of Samsung Biologics stated. “We look forward to continuing to have cooperative relations through this deal in the future.”
The Korea Economic Daily reported that the latest deal increased Samsung Biologics’ total for CMO contracts to $400 million. The company has so far won orders from other multinational pharma firms such as GSK plc that is formerly known as GlaxoSmithKline plc, and Eli Lilly & Co. this year. In comparison, the firm was able to secure $1 billion worth of CMO contracts in 2021.
The South Korean CMO drugmaker obtained contracts from the top pharmaceutical firms in the world, including Bristol Myers Squibb, Roche, Johnson & Johnson, and Merck & Co. It was added that Samsung Biologics also has a contract with Gilead Sciences Inc. in the US.
Meanwhile, Samsung Biologics has been mostly manufacturing antibody treatments recently instead of cell-gene therapy (CGT). It has built up production facilities to make the drug substance for the messenger ribonucleic acid (mRNA)-based COVID-19 vaccines in its plant.
